Skip to main content

Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis.

Publication ,  Journal Article
Scholl, AR; Korentzelos, D; Forns, TE; Brenneman, EK; Kelm, M; Datto, M; Wheeler, SE; Carlsen, ED
Published in: J Appl Lab Med
October 29, 2022

BACKGROUND: Therapeutic monoclonal antibodies can be a source of assay interference in clinical serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), producing monoclonal bands that can be misinterpreted as a monoclonal gammopathy related to a B-cell or plasma cell neoplasm. The extent to which new anti-COVID-19 monoclonal antibodies produce this interference is unknown. METHODS: Casirivimab plus imdevimab, sotrovimab, and bamlanivimab plus etesevimab were spiked into patient serum samples to evaluate for SPEP/IFE interference, to characterize the position of therapy-derived bands relative to a reference band (either combined beta band or beta 1 band, depending on instrument platform), and to confirm heavy and light chain utilization of each medication. Serum samples from patients who had recently received casirivimab plus imdevimab or sotrovimab were also evaluated for comparison. RESULTS: When spiked into serum samples, all tested anti-COVID-19 monoclonal antibodies generated interference in SPEP/IFE. Importantly, the patterns of interference differed between spiked serum samples and serum from patients who had recently received casirivimab plus imdevimab or sotrovimab. CONCLUSIONS: Imdevimab can be added to the growing list of therapeutic monoclonal antibodies that produce sustained interference in SPEP/IFE. Although casirivimab and sotrovimab also produce assay interference in vitro, these antibodies are not reliably detected in serum from recently infused patients. The value of relative band position in recognizing bands that may represent therapeutic monoclonal antibodies is also emphasized. Clinicians and laboratorians should consider therapeutic monoclonal antibody interference in diagnostic SPEP/IFE and review a patient's medication list when new or transient monoclonal bands are identified.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Appl Lab Med

DOI

ISSN

2576-9456

Publication Date

October 29, 2022

Volume

7

Issue

6

Start / End Page

1379 / 1387

Location

England

Related Subject Headings

  • Humans
  • Electrophoresis
  • COVID-19 Drug Treatment
  • COVID-19
  • Antibodies, Monoclonal
  • 3205 Medical biochemistry and metabolomics
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Scholl, A. R., Korentzelos, D., Forns, T. E., Brenneman, E. K., Kelm, M., Datto, M., … Carlsen, E. D. (2022). Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis. J Appl Lab Med, 7(6), 1379–1387. https://doi.org/10.1093/jalm/jfac064
Scholl, Ashley Rose, Dimitrios Korentzelos, Taylor E. Forns, Ethan K. Brenneman, Matthew Kelm, Michael Datto, Sarah E. Wheeler, and Eric D. Carlsen. “Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis.J Appl Lab Med 7, no. 6 (October 29, 2022): 1379–87. https://doi.org/10.1093/jalm/jfac064.
Scholl, Ashley Rose, et al. “Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis.J Appl Lab Med, vol. 7, no. 6, Oct. 2022, pp. 1379–87. Pubmed, doi:10.1093/jalm/jfac064.
Scholl AR, Korentzelos D, Forns TE, Brenneman EK, Kelm M, Datto M, Wheeler SE, Carlsen ED. Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis. J Appl Lab Med. 2022 Oct 29;7(6):1379–1387.

Published In

J Appl Lab Med

DOI

ISSN

2576-9456

Publication Date

October 29, 2022

Volume

7

Issue

6

Start / End Page

1379 / 1387

Location

England

Related Subject Headings

  • Humans
  • Electrophoresis
  • COVID-19 Drug Treatment
  • COVID-19
  • Antibodies, Monoclonal
  • 3205 Medical biochemistry and metabolomics
  • 3202 Clinical sciences